LYRA, US55234L2043

Lyra Therapeutics stock gained 26.67 percent in OTC trading

Published on 10/07/2026 at 03:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Lyra Therapeutics stock reached USD 0.19 on October 5, 2026, with market capitalization at USD 0.3 million. FY2025 revenue fell to USD 398,000.

LYRA, US55234L2043, Illustration mit AI erstellt.

Lyra Therapeutics (ISIN US55234L2043) was last at USD 0.19 in OTC trading on October 5, 2026 at 4:00 p.m. ET, up 26.67 percent from the prior close of USD 0.15. The move puts the small biotechnology company under renewed market scrutiny as its post-split capital structure meets a sharply reduced financial base.

Reverse split resets share count

According to IT Boltwise, Lyra completed a 1-for-50 reverse split on September 22, 2026. The transaction exchanged 50 old shares for one new share, changing the share count and the way historical prices and volumes must be compared.

The reverse split does not itself change the company's operating assets or pipeline. Lyra's investor-relations profile describes LYR-210 and LYR-220 as bioabsorbable nasal inserts designed to deliver six months of continuous mometasone furoate therapy for chronic rhinosinusitis, a clinical focus that still defines the business.

Revenue falls as losses narrow

Fundamentals Hub reports FY2025 revenue of USD 398,000, down from USD 1.53 million in FY2024, a 74.0 percent decline. The same FY2025 figures show a net loss of USD 28.92 million, compared with USD 93.44 million in FY2024.

Cash and equivalents stood at USD 15.89 million at the end of FY2025, while operating cash flow was negative USD 28.86 million. Those figures make financing capacity and the ability to advance clinical programs more material than the mechanical effect of the reverse split.

OTC valuation remains very small

Lyra Therapeutics had a market capitalization of USD 0.3 million and trading volume of 5,469 shares on October 5, 2026. The USD 0.19 last price and 26.67 percent daily gain therefore describe a low-value, thinly traded security rather than a broad repricing of the company's operating results.